695215-93-1

Basic information

• Product Name: 1,3-Benzenedicarboxylic acid, 5-[methyl(methylsulfonyl)amino]-, dimethyl ester
• CAS NO: 695215-93-1
• Molecular Formula: C12H15NO6S
• Molecular Weight: 301.32
• Mol File: 695215-93-1.mol

Chemical Properties

• CAS DataBase Reference: 1,3-Benzenedicarboxylic acid, 5-[methyl(methylsulfonyl)amino]-, dimethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Benzenedicarboxylic acid, 5-[methyl(methylsulfonyl)amino]-, dimethyl ester(695215-93-1)
• EPA Substance Registry System: 1,3-Benzenedicarboxylic acid, 5-[methyl(methylsulfonyl)amino]-, dimethyl ester(695215-93-1)

Safety Data

• Hazardous Substances Data: 695215-93-1(Hazardous Substances Data)

Usage

Molecular Weight

279.29 g/mol

Functional Groups

Benzene ring
Carboxylic acid ester (dimethyl ester)
Amine (methylamino)
Sulfonyl (methylsulfonyl)

Appearance

Solid or crystalline

Potential Applications

Pharmaceutical intermediate for the treatment of various conditions, including inflammation and oxidative stress
Production of polyesters and other polymers
Synthesis of novel materials for various industrial applications

Sectors of Application

Pharmaceutical and industrial sectors

Structure

The molecule consists of a benzene ring with two carboxylic acid ester groups (dimethyl ester) at the 1 and 3 positions, and a methyl(methylsulfonyl)amino group at the 5 position.

Solubility

May be soluble in organic solvents like ethanol, methanol, or acetone

Stability

Stable under normal temperature and pressure, but sensitive to heat, light, and moisture

Reactivity

Can undergo reactions such as hydrolysis, esterification, and amination due to the presence of various functional groups

Safety

Handle with care, as it may have potential hazards depending on its concentration and exposure conditions. It is important to follow proper safety protocols and use appropriate personal protective equipment (PPE) when handling 1,3-Benzenedicarboxylic acid, 5-[methyl(methylsulfonyl)amino]-, dimethyl ester.

Upstream product

• 99-27-4 dimethyl 5-aminoisophthalate 
• 74-88-4 methyl iodide 
• 62814-45-3 5-methanesulphonylamino-isophthalic acid dimethyl ester 

Downstream Products

• 695215-92-0 3-[methyl(methylsulfonyl)amino]-5-((1R)-1-phenylethylaminocarbonyl)benzoate acid 
• 695215-95-3 methyl-3-[methyl(methylsulfonyl)amino]-5-((1R)-1-phenylethylaminocarbonyl)benzoate 
• 1026564-54-4 C₄₁H₇₀N₆O₈SSi 
• 1027373-60-9 C₄₂H₆₉N₅O₈SSi 
• 1025916-59-9 C₄₂H₆₉N₅O₇SSi 
• 1026510-06-4 C₄₁H₆₇N₅O₇SSi 
• 1026742-99-3 C₄₀H₆₈N₆O₈SSi 
• 1026742-93-7 C₃₇H₆₇N₅O₇SSi 
• 940879-56-1 3-{[1-(2,5-dimethyloxazol-4-yl)ethyl]carbamoyl}-5-(N-methylmethan-5-ylsulfonamido)benzoic acid 
• 1026070-16-5 C₁₈H₂₃N₃O₆S 
• 940879-55-0 (S)-3-[(2-hydroxy-1-phenylethyl)carbamoyl]-5-(N-methylmethan-5-ylsulfonamido)benzoic acid 
• 1026309-20-5 C₁₉H₂₂N₂O₆S 
• 940879-54-9 (S)-3-(N-methylmethan-5-ylsulfonamido)-5-((1-phenylethyl)carbamoyl)benzoic acid 
• 940879-53-8 3-(benzylcarbamoyl)-5-(N-methylmethan-5-ylsulfonamido)benzoic acid 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and the claims. The invention also relates to the use thereof for treating Alzheimer's disease (AD) and similar diseases.

COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and in the claims. The invention also relates to the use thereof for treat

ASPARTYL PROTEASE INHIBITORS

The invention provides compounds of the formula (I) N-oxides, addition salts, quaternary amines, metal complexes, stereochemically isomeric forms and metabolites thereof, wherein G is-O-, -S(=O)r-, -CRdRd or -NRa-; W is H, C1-C6

Design, synthesis, and X-ray structure of potent memapsin 2 (β-secretase) inhibitors with isophthalamide derivatives as the P 2 P3-ligands

Structure-based design and synthesis of a number of potent and selective memapsin 2 inhibitors are described. These inhibitors were designed based upon the X-ray structure of memapsin 2-bound inhibitor 3 that incorporates methylsulfonyl alanine as the Ps

β SECRETASE INHIBITOR

Disclosed is a compound represented by the formula (1) below which is useful as a drug for treating Alzheimer's disease, or a pharmaceutically acceptable salt thereof. (1) [In the formula, R1 represents a group represented by the following formula (2): (2) (wherein X represents a nitrogen atom or a group expressed as C(R5); Y represents a nitrogen atom or a group expressed as C(R6); and R5 and R6 independently represent a hydrogen atom or the like) or the like; m represents an integer of 1-6; L1 represents a single bond or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl group or the like; R3 represents a hydrogen atom or the like; L2 represents a single bond or the like; and R4 represents a hydrogen atom, a substituted or unsubstituted aryl group or the like.]

Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease

The present invention is directed to phenylamide and pyridylamide derivative compounds of which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Conformationally biased P3 amide replacements of β-secretase inhibitors

We have synthesized and evaluated a series of conformationally biased P3 amide replacements based on an isophthalamide lead structure. The studies resulted in the identification of the β-secretase inhibitor 7m which has an in vitro IC50 = 35 nM

Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof

The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R1 to R15, A, B, L, i as well as X1-X4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.

COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The present invention provides novel beta-secretase inhibitors of the general formula (I), where the variables A1, A2, L1, L2, L3, R1, R2, R3, R4, R5, R6 and R7 are as defined in the claims, a method for their use in treating Alzheimer's disease, and methods for their use in reducing memapsin 2 catalytic activity.

PYRROLIDIN-3-YL COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention is directed to pyrrolidin-3-yl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The i